Cholangiocarcinoma (CCA) is a form of primary liver cancer with limited therapeutic options. Recently, cancer stem cells (CSCs) have been proposed as a driving force of tumour initiation and dissemination, thus representing a crucial therapeutic target. The protease inhibitor SerpinB3 (SB3) has been identified in several malignancies including hepatocellular carcinoma. SB3 has been involved in the early events of hepatocarcinogenesis and is highly expressed in hepatic progenitor cells and in a mouse model of liver progenitor cell activation. However, only limited information on the possible role of SB3 in CCA stem-like compartment is available.

中文翻译：

---

蛋白酶抑制剂 SerpinB3 作为人胆管癌干细胞样亚群的关键调节剂

胆管癌 (CCA) 是一种治疗选择有限的原发性肝癌。最近，癌症干细胞（CSCs）被认为是肿瘤发生和传播的驱动力，因此代表了一个关键的治疗靶点。蛋白酶抑制剂 SerpinB3 (SB3) 已在包括肝细胞癌在内的几种恶性肿瘤中得到鉴定。SB3 参与了肝癌发生的早期事件，并且在肝祖细胞和肝祖细胞活化的小鼠模型中高度表达。然而，关于 SB3 在 CCA 茎状隔室中的可能作用的信息有限。